Reduction of false-negative papillary thyroid carcinomas by the routine analysis of BRAFT1799A mutation on fine-needle aspiration biopsy specimens: A prospective study of 814 thyroid FNAB patients

Annals of Surgery

Volumn 255, Issue 5, 2012, Pages 986-992

  Cañadas Garre, Marisa ^a   Becerra Massare, Patricia ^a   De La Torre Casares, Martín López ^a   Villar Del Moral, Jesús ^a   Céspedes Mas, Susana ^a   Vílchez Joya, Ricardo ^a   Muros De Fuentes, Teresa ^a   García Calvente, Carlos ^a   Piédrola Maroto, Gonzalo ^a   López Nevot, Miguel A ^a   Montes Ramírez, Rosa ^b   Llamas Elvira, José M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ADULT; ARTICLE; ASPIRATION BIOPSY; CYTOPATHOLOGY; FALSE NEGATIVE RESULT; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; THYROID NODULE; THYROID PAPILLARY CARCINOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; DNA, NEOPLASM; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84859907024     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31824e8d70     Document Type: Article

References (51)

1. Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008;22:901-911.
2. Filetti S, Durante C, TorlontanoM.Nonsurgical approaches to themanagement of thyroid nodules. Nat Clin Pract Endocrinol Metab. 2006;2:384-394. (Pubitemid 44050108)
3. Schlumberger M, Pacini F. Nodular thyroid disease: thyroid nodule. In: Schlumberger M, Pacini F. Thyroid Tumors. Paris, France: ́ Editions Nucĺeon; 1999:13-30.
4. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83:2638-2648. (Pubitemid 29019586)
5. Albores-Saavedra J, Henson DE, Glazer E, et al. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18:1-7. (Pubitemid 47345617)
6. Gharib H, Papini E, PaschkeR. Thyroid nodules: a reviewof current guidelines, practices, and prospects. Eur J Endocrinol. 2008;159:493-505.
7. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Associationmanagement guidelines for patientswith thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
8. Kini SR. Thyroid Cytopathology. An Atlas and Text. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
9. Sangalli G, Serio G, Zampatti C, et al. Fine needle aspiration cytology of the thyroid: a comparison of 5469 cytological and final histological diagnoses. Cytopathology. 2006;17:245-250. (Pubitemid 44379237)
10. Chow LS, Gharib H, Goellner JR, et al. Nondiagnostic thyroid fine-needle aspiration cytology: management dilemmas. Thyroid. 2001;11:1147-1151. (Pubitemid 34041895)
11. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36:425-437. (Pubitemid 351829800)
12. Tee YY, Lowe AJ, Brand CA, et al. Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review. Ann Surg. 2007;246:714-720. (Pubitemid 350035645)
13. Yeh MW, Demircan O, Ituarte P, et al. False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. Thyroid. 2004;14:207-215. (Pubitemid 38452193)
14. Xing M.BRAFmutation in thyroid cancer. EndocrRelat Cancer. 2005;12:245-262.
15. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 2010;321:86-93.
16. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28:742-762. (Pubitemid 350294294)
17. Marchetti I, Lessi F, Mazzanti CM, et al. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid. 2009;19: 837-842.
18. Zatelli MC, Trasforini G, Leoni S, et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol. 2009;161:467-473.
19. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092-2098.
20. Kim SW, Lee JI, Kim JW, et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab. 2010;95:3693-3700.
21. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954. (Pubitemid 34716871)
22. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627. (Pubitemid 36553510)
23. Cohen Y, Goldenberg-Cohen N, Parrella P, et al. Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:2876-2878. (Pubitemid 36759747)
24. Pearson WR, Wood T, Zhang Z, et al. Comparison of DNA sequences with protein sequences. Genomics. 1997;46:24-36. (Pubitemid 27527688)
25. Galen RS, Gambino SR. Beyond Normality: The Predictive Value and Efficiency of Medical Diagnoses. New York, NY: John Wiley & Sons;1975;1-14.
26. Cibas ES, Ali SZ; NCI Thyroid FNA State of the Science Conference. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132:658-665.
27. Saleh HA, Feng J, Tabassum F, et al. Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. Cytojournal. 2009;6:18.
28. Barut F, Kandemir NO, Bektas S, et al. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol. 2010;21:80-89.
29. Kim MJ, Kim HJ, Hong SJ, et al. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Acta Cytol. 2006;50:28-34. (Pubitemid 43157428)
30. Sapio MR, Guerra A, Posca D, et al. Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer. 2007;14:1089-1097. (Pubitemid 351252440)
31. Sapio MR, Posca D, Raggioli A, et al. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf). 2007;66:678-683. (Pubitemid 46699541)
32. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:5175-5180. (Pubitemid 39391466)
33. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092-2098.
34. Pizzolanti G, Russo L, Richiusa P, et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid. 2007;17:1109-1115. (Pubitemid 350207747)
35. Musholt TJ, Fottner C, Weber MM, et al. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg. 2010;34:2595-2603.
36. Marotta V, Guerra A, Sapio MR, et al. Growing thyroid nodules with benign histology and RET rearrangement. Endocr J. 2010;57:1081-1087.
37. Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95:1365-1369.
38. Kumagai A, Namba H, Akanov Z, et al. Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr J. 2007;54:399-405. (Pubitemid 47105427)
39. Cañadas Garre M, Ĺopez de la Torre Casares M, Becerra Massare P, et al. BRAFT1799A mutation in the primary tumour as a risk, recurrence or persistence indicator in papillary thyroid carcinoma. Endocrinol Nutr. 2011;58: 175-184.
40. Amrikachi M, Ramzy I, Rubenfeld S, et al. Accuracy of fine-needle aspiration of thyroid. Arch Pathol Lab Med. 2001;125:484-488.
41. Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009;146:1215-1223.
42. Cohen Y, Rosenbaum E, Clark DP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res. 2004;10:2761-2765. (Pubitemid 38509152)
43. Rowe LR, Bentz BG, Bentz JS. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal. 2006;3:10.
44. Chung KW, Yang SK, Lee GK, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAFV600E mutation-prevalent area. Clin Endocrinol (Oxf). 2006;65:660-666. (Pubitemid 44583829)
45. Bentz BG, Miller BT, Holden JA, et al. B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules. Otolaryngol Head Neck Surg. 2009;140:709-714.
46. Moon HJ, Kwak JY, Kim EK, et al. The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology. Ann Surg Oncol. 2009;16:3125-3131.
47. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance." Cancer Cytopathol. 2010;118:17-23.
48. HayashidaN,Namba H,KumagaiA, et al.Arapid and simple detectionmethod for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid. 2004;14:910-915. (Pubitemid 39612909)
49. Jo YS, Huang S, Kim YJ, et al. Diagnostic value of pyrosequencing for the BRAF V600E mutation in US-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf). 2009;70:139-144.
50. Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009;27:2977-2982.
51. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375-381; discussion 381-384. (Pubitemid 47312122)